UROGESIC-BLUE™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.
One tablet orally 4 times per day followed by liberal fluid intake. Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.
Rx Only
Each tablet contains:
| Methenamine, USP | 81.6 mg | |
| Monobasic Sodium Phosphate, USP | 40.8 mg | |
| Methylene Blue, USP | 10.8 mg | |
| Hyoscyamine Sulfate, USP | 0.12 mg |
Inactive Ingredients include: microcrystalline cellulose, NF, mannitol, USP, croscarmellose sodium, NF, magnesium stearate, NF and lake blend blue.
HYOSCYAMINE SULFATE is an alkaloid of belladonna. Exists as a white crystalline powder. Affected by light It is very soluble in water; freely soluble in alcohol; practically insoluble in ether.
METHENAMINE exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water; soluble in alcohol and in chloroform.
METHYLENE BLUE exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.
MONOBASIC SODIUM PHOSPHATE exists as a white crystalline powder. Its solutions are acidic to litmus. It is freely soluble in water and practically insoluble in alcohol.
HYOSCYAMINE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate.
METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70% to 90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding: some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.
METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed in the gastrointestinal tract and is rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged.
MONOBASIC SODIUM PHOSPHATE helps to maintain an acid pH in the urine necessary for the degradation of methenamine.
UROGESIC-BLUE™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.
UROGESIC-BLUE™ is contraindicated in patients with a hypersensitivity to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).
Do not exceed recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs discontinue use immediately.
patients intolerant of belladonna alkaloids may be intolerant of this medication also.
hyoscyamine and methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether UROGESIC-BLUE™ tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. UROGESIC-BLUE™ tablets should be given to a pregnant woman only if clearly needed.
problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk.
there have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.
infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.
use with caution in elderly patients as they may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness, or confusion.
because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opoid (narcotic) analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria).
Patients should be advised that the urine may become blue to blue green and the feces may be discolored as a result of the excretion of methylene blue.
Cardiovascular – rapid pulse, flushing
Central Nervous System – blurred vision, dizziness
Respiratory – shortness of breath or troubled breathing
Genitourinary – difficulty micturition, acute urinary retention
Gastrointestinal – dry mouth, nausea/vomiting
A dependence on the use of UROGESIC-BLUE™ has not been reported and due to the nature of its ingredients, abuse of UROGESIC-BLUE™ is not expected.
Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 mg to 4 mg (0.5 mg to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary.
One tablet orally 4 times per day followed by liberal fluid intake.
Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.
UROGESIC-BLUE™ are light blue to blue, oval, biconvex tablets debossed with "ED UB" with scoreline on one side and plain on the other side. Supplied in bottles of 100 tablets (NDC 0485-0151-01).
RX ONLY
Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to 86° F) (See USP Controlled Room Temperature). Keep container tightly closed.
Manufactured for:
Edwards Pharmaceutical, Inc.
111 W. Mulberry St. Ripley, Mississippi 38663
Manufactured by:
Belcher Pharmaceuticals, LLC
Largo, FL 33777
May 2011 R-0110B
NEW
FORMULATION
NDC 0485-0151-01
UROGESIC-BLUE™
URINARY ANTISEPTIC
ANTISPASMODIC
DESCRIPTION:
Each tablet contains:
Methenamine, USP 81.6 mg
Monobasic Sodium Phosphate, USP 40.8 mg
Methylene Blue, USP 10.8 mg
Hyoscyamine Sulfate, USP 0.12 mg
CONTENTS: 100 TABLETS
RX ONLY
Manufactured for
EDWARDS
PHARMACEUTICAL, INC.
Berwyn, PA
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1050325 | methenamine 81.6 MG / sodium phosphate, monobasic 40.8 MG / methylene blue 10.8 MG / hyoscyamine sulfate 0.12 MG Oral Tablet | PSN | 6 |
| 1251290 | UROGESIC-BLUE 81.6 MG / 40.8 MG / 10.8 MG / 0.12 MG Oral Tablet, Reformulated Apr 2012 | PSN | 6 |
| 1251290 | hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Urogesic Blue Reformulated Apr 2012] | SBD | 6 |
| 1050325 | hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet | SCD | 6 |
| 1251290 | Urogesic Blue (hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG) Oral Tablet, Reformulated Apr 2012 | SY | 6 |
| Class | Version | Type | Effective |
|---|---|---|---|
| METHYLENE BLUE CATION Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| SODIUM CATION Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 0485-0151-01 | 2025-08-19 | C162847 | 48780-1 | 3b156c62-2599-fb37-e063-e6dba90a4e07 | UROGESIC-BLUE™ |
| 0485-0151-01 | 2025-07-29 | C162847 | 48780-1 | 3b156c62-2599-fb37-e063-e6dba90a4e07 | UROGESIC-BLUE™ |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0485-0151-01 | UROGESIC BLUE | 100 in 1 BOTTLE, PLASTIC | TABLET, COATED | 100 | 6 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0485-0151-01 | EA - Each | 0485-0151 | b6d2b268-e65b-455d-ae8b-87dfc7c59fdb | 1 | 2013-03-03 |
| 0485-0151-30 | EA - Each | 0485-0151 | a14ff71e-902f-47cc-aeed-0822723514c2 | 1 | 2015-03-03 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYOSCYAMINE SULFATE | ACTIVE INGREDIENT | F2R8V82B84 | 1 | |
| METHENAMINE | ACTIVE INGREDIENT | J50OIX95QV | 1 | |
| METHYLENE BLUE | ACTIVE INGREDIENT | T42P99266K | 1 | |
| SODIUM PHOSPHATE, MONOBASIC | ACTIVE INGREDIENT | 3980JIH2SW | 1 | |
| HYOSCYAMINE | ACTIVE MOIETY | PX44XO846X | 1 | |
| METHENAMINE | ACTIVE MOIETY | J50OIX95QV | 1 | |
| METHYLENE BLUE CATION | ACTIVE MOIETY | ZMZ79891ZH | 1 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0485-0151 | 0485-0151-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CELLULOSE, MICROCRYSTALLINE | OP1R32D61U | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| METHENAMINE | J50OIX95QV | ACTIB |
| SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | ACTIB |
| METHYLENE BLUE | T42P99266K | ACTIB |
| HYOSCYAMINE SULFATE | F2R8V82B84 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, COATED / ORAL | 920 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| UROGESIC BLUE | METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, AND HYOSCYAMINE SULFATE | EDWARDS PHARMACEUTICALS, INC. | f650dd78-615c-42d3-9b2d-3a989039d80c | 2026-03-05 | Warnings, Adverse reactions | 0485-0151-01 0485-0151 00485015101 4c489292-1d09-11a5-e063-6394a90a9537 f650dd78-615c-42d3-9b2d-3a989039d80c |
| UROGESIC BLUE | METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, AND HYOSCYAMINE SULFATE | EDWARDS PHARMACEUTICALS, INC. | d820e42d-ad2b-4e11-907b-a94d698ca285 | 2025-08-13 | Warnings, Adverse reactions | 0485-0151 |
Adverse event summaries are temporarily unavailable. Other product information remains available.